Blood Preservation Composition Reducing Hemolysis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for preserving blood components, particularly red blood cells and platelets, are limited by short shelf life, leading to storage lesions and reduced hemostatic activity, resulting in suboptimal clinical outcomes and high discard rates.

Innovation Solution

A composition including triciribine, its metabolites, analogs, and prodrugs, along with anticoagulants and buffers, is used to contact red blood cells and platelets, enhancing their storage and rejuvenation by reducing hemolysis and maintaining functional integrity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If standard preservation solutions (CPD, CPDA) are used to store red blood cells, then the storage duration can be extended to 42 days, but storage lesions occur including hemolysis, ATP depletion, and morphological changes

Engineering Contradiction:

Improvestorage durationVSAvoidcell integrity

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent modifies the chemical composition parameters of the preservation solution by incorporating antioxidants (vitamin E, vitamin C), metabolic substrates (pyruvate, lactate, bicarbonate), and growth factors (IL-3, G-CSF) to create an optimized storage environment that maintains RBC integrity for extended periods while preventing storage lesions

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The preservation solution is formulated as a composite containing multiple components working synergistically: anticoagulants (citrate, heparin), buffers (phosphate, bicarbonate), energy substrates (dextrose, pyruvate), antioxidants, and cytokines, each addressing specific aspects of RBC preservation to collectively extend shelf life while maintaining cell quality

Inventive Principle:

Principle #40Composite materials

2Productivity

If blood components are separated for component therapy, then multiple patients can benefit from each unit of blood, but the separation process causes detrimental effects on RBCs including decreased ATP and 2,3-DPG levels

Engineering Contradiction:

Improveutilization efficiencyVSAvoidRBC function

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies preservation solutions containing metabolic substrates and protective agents to RBCs before separation and during storage, pre-establishing conditions that protect against the detrimental effects of component separation and subsequent storage, thereby maintaining RBC functionality despite the separation process

Inventive Principle:

Principle #10Preliminary action

3Duration of action of stationary object

If platelets are stored for extended periods to reduce discard rates, then hemostatic activity is maintained, but storage lesions develop reducing platelet function

Engineering Contradiction:

Improveshelf lifeVSAvoidhemostatic activity

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The preservation solution for platelets contains growth factors (IL-3, G-CSF) and metabolic substrates that enable platelets to maintain their own viability and function during storage by supporting continuous low-level metabolism and preventing activation, allowing extended storage while maintaining hemostatic activity

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS11779012B2Compositions and methods for preserving red blood cells and platelets

Publication Date: 2023.10.10 RYTHRX THERAPEUTICS

AI summary

Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets.